Compact, watertight, and rechargeable via a micro USB port, the t:slim X2™ insulin pump can integrate with Dexcom G6 continuous glucose monitoring (CGM).* When integrated with CGM, patients can use either Control‑IQ™ or Basal-IQ® technology.EXPLORE THE t:slim X2
The t:slim X2 insulin pump can be used with or without CGM. When CGM is turned off, the Bolus and Options buttons are placed in the center of the screen for easy access.
Optional Control-IQ (advanced hybrid closed loop) or Basal-IQ (predictive low glucose suspend) technologies are designed to reduce and prevent lows before they happen.
Uncover meaningful insights and trends to help fine tune patient therapy using our t:connect® web application. Data can be viewed and printed from a single, user-friendly webpage.
Control-IQ technology uses an algorithm to automatically adjust insulin in response to predicted glucose levels to help increase time in the American Diabetes Association-recommended target glucose range (70-180 mg/dL).†
Control-IQ advanced hybrid closed-loop technology on the t:slim X2 insulin pump is designed to help increase time in range (70-180 mg/dL)† using Dexcom G6 CGM values to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly; including delivery of automatic correction boluses as needed.‡
Control-IQ technology adjusts insulin delivery to help prevent highs and lows, while still allowing the user to manually bolus for meals.
The Control-IQ system on the t:slim X2 pump delivers automatic correction boluses, up to 60% once per hour to help prevent highs.
Dedicated settings for Sleep and Exercise Activities adjust treatment values to better match different needs when activities are enabled.EXPLORE CONTROL-IQ
Basal-IQ technology helps reduce the frequency and duration of low-glucose events by using Dexcom G6 CGM values to predict glucose levels 30 minutes ahead and suspending insulin if they are expected to drop below 80 mg/dL, or if a CGM reading falls below 70 mg/dL.
PLGS technology is particularly beneficial to patients who don’t always recognize when their glucose level is dropping.
In studies, Basal-IQ technology reduced time spent below 70 mg/dL by 31% and demonstrated no rebound hyperglycemia.2
The Basal-IQ feature on the t:slim X2 insulin pump has no complicated settings to manage. It operates in the background without constant input or interaction.EXPLORE BASAL-IQ
Upload, view, and print patient data using the dedicated t:connect HCP web application. Manage data from Tandem insulin pumps, supported glucose meters,§ and CGM devices.^Learn More
The t:slim X2 insulin pump is the first FDA-approved insulin pump capable of remote feature updates.** Using a personal computer, patients can keep their pump up to date with the latest technology during its warranty period. In‑warranty Tandem patients will receive no-cost software updates for t:slim X2 insulin pump through the end of 2020.
We offer a variety of infusion set options to give our Tandem pump users a choice of cannula materials, tubing lengths, insertion angles, and insertion techniques. Your patients also have access to supplementary instructional videos on the Tandem Diabetes Care patient website.
* CGM sold separately.
† As measured by CGM.
‡ If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus with a target of 110 mg/dL and delivers 60% of that value. It will do this up to once per hour as needed.
§ The t:connect application is compatible with the following meters: OneTouch Verio IQ, OneTouch UltraMini, OneTouch Ultra 2, FreeStyle Lite, FreeStyle Freedom Lite, ACCU-CHEK Aviva, ACCU-CHEK Compact Plus.
^ CGM data requires a CGM-enabled Tandem insulin pump.
** Additional feature updates are not currently available for the t:slim X2 pump with Basal-IQ or Control-IQ technology and are subject to future FDA approvals. A prescription and additional training may be required to access certain future software updates. Offer only available to customers who reside in the United States, who are in warranty at the time they update their pump and who purchased a t:slim X2 insulin pump on or before December 31, 2020. Tandem may discontinue select software and features over time at its discretion. This is a limited time offer and Tandem reserves the right to discontinue this program at its discretion.
1. 38% smaller than MiniMed 630G and 670G and at least 28% smaller than MiniMed 530G, Animas Vibe, and Omnipod System. Data on file, Tandem Diabetes Care.
2. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial [published online August 8, 2018]. Diabetes Care. doi:10.2337/dc18-0771.
Important Safety Information
Caution: Federal (USA) law restricts the t:slim X2 insulin pump, the t:slim X2 pump with Basal-IQ technology, and Control-IQ technology to sale by or on the order of a physician. The t:slim X2 pump, the t:slim X2 pump with Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, the t:slim X2 pump with Basal-IQ technology, and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.
t:slim X2 insulin pump: The t:slim X2 insulin pump with integrated technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. t:slim X2 insulin pump with Basal-IQ technology: When used with a compatible integrated continuous glucose monitor (iCGM), the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The t:slim X2 pump with Basal-IQ technology is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.
|WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.|
Control-IQ technology and the t:slim X2 pump with Basal-IQ technology are not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the t:slim X2 pump, the t:slim X2 pump with Basal-IQ technology, and Control-IQ technology must: be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit www.tandemdiabetes.com/safetyinfo.